New combo aims to slow pancreatic cancer in Second-Line treatment
NCT ID NCT06015659
First seen Feb 10, 2026 · Last updated Apr 30, 2026 · Updated 11 times
Summary
This study tests whether combining the experimental drug ZN-c3 with the chemotherapy gemcitabine can help control advanced pancreatic cancer that has worsened after initial treatment. The trial includes 12 adults whose cancer is not curable with standard therapies. Researchers are measuring how many patients are alive without their cancer growing six months after starting the combination.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.